| Reference number |
2026-00421 |
| Coordinator |
Key2Brain AB |
| Funding from Vinnova |
SEK 25 000 |
| Project duration |
April 2026 - April 2026
|
| Status |
Ongoing |
| Call |
Travel grant Vinnova 2026 |
Purpose and goal
Our motivation to participate is guided by our strategic ambition to collaborate early with world-leading pharmaceutical companies.
Expected effects and result
Participating in Tokyo and Seoul will give us the opportunity to showcase our technology and internal pipeline initiatives, while also opening up direct contact with knowledgeable partners and investors in our area of expertise. We expect to establish new relationships and aim to sign at least one new agreement.
Planned approach and implementation
The timing of the conference is perfect for Key2Brain: With our recent partnership in South Korea with OliX Pharmaceuticals, we have an excellent foundation to build on in Asia. We will actively participate in all partnering meetings and have already booked meetings with several potential partners.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
